Study of the NATURal History, Epidemiological, Clinical, Diagnostic and Therapeutic Aspects of CELiac Disease and Non-celiac Enteropathies

NATURCEL Registry: Study of the NATURal History, Epidemiological, Clinical, Diagnostic and Therapeutic Aspects of CELiac Disease and Non-celiac Enteropathies

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07070596

Acronym

NATURCEL

Enrollment

1000

Registered

2025-07-17

Start date

2025-06-01

Completion date

2030-01-01

Last updated

2025-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Celiac Disease

Keywords

Gluten-Related Disorders, Gluten-Free Diet, HLA-DQ2, HLA-DQ8, Tissue Transglutaminase Antibodies, Anti-Endomysial Antibodies, Pediatric and Adult Celiac Disease, TCRγδ+ lymphocytes

Brief summary

Celiac disease is a chronic immune-mediated enteropathy triggered by gluten intake, which affects the small intestine in genetically susceptible subjects (HLA-DQ2 and/or HLA-DQ8). Affecting both children and adults, it is among the most common genetically determined disorders in Western countries. The disease is characterized by clinical manifestations (mainly digestive symptoms and signs of intestinal malabsorption), the presence of specific antibodies (tissue transglutaminase and endomysium) and enteropathy. Currently, the only treatment for celiac disease is a strict gluten-free diet for life. The main objective of the NATURCEL registry (Study of the NATURal history, epidemiological, clinical, diagnostic and therapeutic aspects of celiac disease and non-celiac enteropathies) is to collect a wide range of data (epidemiological, clinical, genetic, immunological, etc.) for scientific and translational purposes. The registry will include individuals diagnosed with celiac disease or other gluten-related disorders, as well as patients with non-celiac enteropathies evaluated for suspected celiac disease. In the future, the project also aims to establish a biobank-an organized repository of biological samples-to further support scientific and medical research in this field.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Individuals under diagnostic evaluation for celiac disease

Exclusion criteria

* Failure to sign informed consent

Design outcomes

Primary

Measure	Time frame
Proportion of patients with confirmed celiac disease diagnosis based on serologic and histologic criteria among those with suspected celiac disease	End of diagnostic evaluation (up to 10 weeks after inclusion)

Countries

Spain

Contacts

Primary ContactAlbert Martín-Cardona, MD

malaltiaceliaca@mutuaterrassa.cat(0034)937365050

Outcome results